Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily.
For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking.
To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73
m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Improves blood glucose control in adults with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to improve blood glucose control in adult patients with type 2 diabetes and is best used in conjunction with diet and exercise therapies. Empagliflozin, sitagliptin, and metformin work together to effectively control blood sugar levels. As a result, blood glucose levels are stabilized, aiding in diabetes management. If taken safely and consistently, positive effects on blood glucose control can be expected.
How to take
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily.
For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg.
For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking.
To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73
m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This medication contains sitagliptin, empagliflozin, and metformin, which help improve blood glucose control.
Sitagliptin may rarely cause serious allergic reactions, so if symptoms like skin rash or difficulty breathing occur, usage must be stopped immediately and a doctor should be consulted.
Furthermore, acute pancreatitis may occur, so if symptoms such as abdominal pain or vomiting appear, healthcare personnel should be informed immediately.
Metformin may rarely cause a serious side effect known as lactic acidosis, so if symptoms like sudden fatigue, muscle pain, or difficulty breathing appear, a hospital visit is required immediately.
This medication should not be used in patients with type 1 diabetes, severe renal impairment, acute heart failure, or severe infections.
Especially in cases of impaired renal function, kidney function tests should be performed before administration, and if necessary, dose adjustments or cessation of therapy should be considered.
Additionally, if surgery or iodinated contrast examinations are planned, discontinuation of this medication should occur 48 hours prior to the examination and it should only be resumed once renal function has been confirmed to be normal.
There is a risk of hypoglycemia with this medication, so blood glucose changes should be closely monitored when taken alongside insulin or sulfonylureas.
Infections may occur during treatment, particularly urinary tract infections or genital infections, so prompt treatment should be sought if relevant symptoms arise.
Dehydration or hypotension may pose risks due to fluid loss, so patients with dehydration symptoms or the elderly should exercise caution.
Patients with liver dysfunction should avoid this medication, and excessive alcohol consumption should also be avoided.
Regular blood tests and kidney function assessments are crucial while taking this medication to detect and manage adverse reactions early.
If blisters or severe joint pain occur, it is important to inform a doctor immediately as such symptoms may necessitate drug discontinuation.
Caution is advised when driving or operating machinery due to the risk of hypoglycemia, particularly if used with insulin or sulfonylureas.
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness for a longer period.
Appearance and packaging
Appearance
Blue double convex oval extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.